| P2093 | author name string | Allan H Young | |
| | Paul A Keedwell | |
| P2860 | cites work | Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials | Q22241689 |
| | Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication | Q22253024 |
| | Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies | Q27499305 |
| | Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression | Q28247703 |
| | Pramipexole for bipolar II depression: a placebo-controlled proof of concept study | Q28268655 |
| | GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects | Q30440925 |
| | Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP | Q30569917 |
| | The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders | Q30583384 |
| | Historical perspectives and natural history of bipolar disorder | Q33920209 |
| | Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). | Q34000973 |
| | Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis | Q34090603 |
| | A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). | Q34096127 |
| | Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995-2009. | Q34098311 |
| | Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). | Q34230151 |
| | Efficacy of electroconvulsive therapy in bipolar versus unipolar major depression: a meta-analysis. | Q34261592 |
| | Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression | Q34275783 |
| | Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series | Q34344076 |
| | The HCL-32: towards a self-assessment tool for hypomanic symptoms in outpatients | Q34446218 |
| | Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review | Q34574031 |
| | The phenomenology of bipolar disorder: what drives the high rate of medical burden and determines long-term prognosis? | Q35841353 |
| | ECNP consensus meeting. Bipolar depression. Nice, March 2007. | Q37172336 |
| | Emerging drugs for major depressive disorder | Q37984619 |
| | A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). | Q38376026 |
| | Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. | Q42537403 |
| | Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study | Q42664825 |
| | An open trial of pregabalin as an acute and maintenance adjunctive treatment for outpatients with treatment resistant bipolar disorder | Q42671366 |
| | Dose-response relationship of selective serotonin reuptake inhibitors treatment-emergent hypomania in depressive disorders | Q43725413 |
| | Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy | Q43846648 |
| | Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers | Q43931805 |
| | Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. | Q44142664 |
| | A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder | Q44403599 |
| | Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression - low manic switch rate | Q44783521 |
| | Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone | Q44824135 |
| | Costs of the principal mood disorders: a study of comparative direct and indirect costs incurred by those with bipolar I, bipolar II and unipolar disorders | Q45143830 |
| | An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression | Q45260842 |
| | Annual cost of managing bipolar disorder to the UK healthcare system | Q45337375 |
| | Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy | Q46096383 |
| | Divalproex in the treatment of bipolar depression: a placebo-controlled study | Q46394405 |
| | Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression--lack of manic induction | Q46516221 |
| | A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression | Q46580881 |
| | Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes | Q46775574 |
| | Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers | Q46921505 |
| | SSRIs as mood stabilizers for Bipolar II Disorder? A proof of concept study | Q46974782 |
| | Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression | Q48141962 |
| | A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode | Q48721347 |
| | Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. | Q50929769 |
| | Sub-threshold manic symptoms in recurrent major depressive disorder are a marker for poor outcome. | Q51873563 |
| | Medical resource use among patients treated for bipolar disorder: a retrospective, cross-sectional, descriptive analysis. | Q51951926 |
| | Lithium carbonate and imipramine in prevention of affective episodes. A comparison in recurrent affective illness. | Q53965654 |
| | Treatment of cyclothymic disorder: commentary. | Q55054028 |
| | Efficacy and Safety of Lamotrigine as Add-On Treatment to Lithium in Bipolar Depression | Q57612633 |
| | Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment | Q57612798 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bipolar depression | Q56014658 |
| P304 | page(s) | 25-36 | |
| P577 | publication date | 2014-01-08 | |
| P1433 | published in | Expert Opinion on Emerging Drugs | Q5421207 |
| P1476 | title | Emerging drugs for bipolar depression: an update | |
| P478 | volume | 19 | |